DOI: 10.36347/sjams.2022.v10i08.018

Pages: 1271-1276

Introduction: Bronchogenic carcinoma accounts for about one-third of all cancer deaths among males. The inclination is such among females as well. This disease is more communal in males than females. Decreasing the number of fractions required for palliative care should be of understandable advantage for both individual patients and the usage of radiotherapy resources. Methods: This prospective study was carried out in Sylhet MAG Osmani Medical College & Hospital from 1st July 2020 to 30th June 2021 to determine the effects of hypofractionated radiotherapy in an advanced stage of bronchogenic carcinoma. Completed data forms were reviewed, edited, and processed for computer data entry. The data analysis was performed using Statistical Package for the Social Sciences (SPSS) Version 25.0. Result: The age of the patients ranged from 41-70 years and the maximum prevalence of the disease was seen above the 50s. The male- to-female ratio was 6:1 in the intervention arm and 14:1 in the control arm. The male gender is predominant. All the male patients were tobacco smokers and the females were passive smokers. Lung cancer was found most in cultivators in this study. Cough, chest pain, dyspnoea and haemoptysis were considered as parameters of symptoms. Most of the patients presented with cough, chest pain, dyspnoea and some with haemoptysis. In Arm A, 67% of patients got relief from all the symptoms during treatment time. In the rest 33%, early side effects were developed and treated accordingly. Ultimately 87% of patients got relief from all the symptoms within 2 weeks of completion of treatment. In 13% of cases, there was no relief. In Arm B, 74% of cases got relief from all the symptoms during treatment time. In the rest 26% of cases, adverse reactions developed. These subsided automatically in some cases and others, supportive treatment was required. Finally, 83.33% of cases became free of symptoms and 16.67% of cases were having no symptomatic relief. ...........